Core Insights - Biomea Fusion Inc. is recognized as an overlooked growth stock with a Buy rating and a price target of $8 initiated by Rodman & Renshaw [1][3] Company Strategy - In Q3 2025, Biomea Fusion announced a strategic shift to focus on two primary assets: icovamenib, a menin inhibitor for type 2 diabetes, and BMF-650, an oral GLP-1 receptor agonist for obesity [2][4] - Icovamenib aims to regenerate healthy insulin-producing beta cells by partially inhibiting menin, potentially offering a disease-modifying treatment for diabetes [2] Clinical Data - Biomea Fusion reported durable 52-week data from its Phase II COVALENT-111 study, showing a sustained 1.5% mean reduction in HbA1c nine months after a 12-week course of icovamenib in patients with severe insulin-deficient type 2 diabetes [3] - Patients who previously failed to reach glycemic targets on GLP-1 therapies experienced a 1.3% reduction in HbA1c, indicating a legacy effect of the treatment [3]

Core Insights - Biomea Fusion, Inc. is entering 2026 with strong operational momentum and a clear plan for its investigational metabolic programs, focusing on icovamenib and BMF-650 [1][2] Icovamenib Development - Icovamenib is a potentially first-in-class covalent menin inhibitor that promotes beta-cell proliferation and improves beta-cell function, targeting insulin-deficient diabetes [3][4] - Recent 52-week data indicates sustained glycemic improvement in patients with insulin deficiency, reinforcing its differentiated approach [3][4] - The therapy has shown clinically meaningful benefits for patients on GLP-1 therapies who have not achieved glycemic targets, supporting its use alongside incretin-based treatments [4] - A food-effect study demonstrated optimal pharmacokinetic exposure and a favorable safety profile, which is crucial for upcoming Phase II studies [5][6] - Over 400 subjects have been dosed with icovamenib, indicating a generally well-tolerated safety profile [6] BMF-650 Development - BMF-650 is an oral next-generation GLP-1 receptor agonist designed for effective and patient-friendly metabolic care [7][8] - Initial 28-day weight loss clinical data from the Phase I study in obese volunteers is expected in Q2 2026 [8] 2026 Milestones - The company plans to advance icovamenib in two Phase II clinical trials, COVALENT-211 and COVALENT-212, with first patient enrollment expected in Q1 2026 and readouts anticipated in Q4 2026 [14] - Continued proactive regulatory engagement and collaboration with clinical experts will support progression toward late-stage development [14]

Core Insights - Several biotech and therapeutics companies experienced significant gains in after-hours trading on December 2, 2025, driven by corporate updates, investor anticipation, and scientific disclosures [1] Company Updates - Clene Inc. (CLNN) shares surged 8.53% to $10.05 after a regular session close of $9.26, following the announcement of an upcoming update on its CNM-Au8 program for ALS, which is expected to boost investor optimism [2] - Werewolf Therapeutics, Inc. (HOWL) advanced 6.12% to $0.91, recovering from a decline, as investors reacted to the company's presentation at the Society for Immunotherapy of Cancer's Annual Meeting and its narrower Q3 net loss of $16.4 million compared to the previous year [3] - Biomea Fusion, Inc. (BMEA) gained 7.31% to $1.03 after announcing its selection for an oral presentation at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease, showcasing advancements in metabolic disease research [4] - Denali Therapeutics Inc. (DNLI) rose 3.14% to $18.40 despite no new news, indicating steady investor interest in the neurodegenerative disease sector [5] - TScan Therapeutics, Inc. (TCRX) added 3.97% to $0.99, recovering from a drop, with Q3 revenue growth reported at $2.5 million, up from $1.0 million a year earlier, despite widening net losses to $35.7 million [6] - Nyxoah SA (NYXH) climbed 4.03% to $4.90, following an increase in insider voting rights to 10.14%, reflecting growing insider ownership [7] - Dyne Therapeutics, Inc. (DYN) rose 4.80% to $20.95, despite widening net losses to $108.0 million in Q3, compared to $97.1 million a year earlier, as it advances its muscle disease therapy pipeline [8] - Outlook Therapeutics, Inc. (OTLK) gained 3.83% to $1.90, with no new updates but reflecting investor positioning ahead of regulatory milestones for its ophthalmic drug candidate [9]

Core Insights - Biomea Fusion, Inc. has initiated a Phase I clinical trial for BMF-650, a next-generation oral small molecule GLP-1 receptor agonist aimed at treating obesity [1][4] - BMF-650 is designed to enhance oral bioavailability and reduce pharmacokinetic variability, potentially leading to better weight reduction outcomes for patients [2][5] Company Overview - Biomea Fusion is focused on developing oral small molecule therapies for diabetes and obesity, with BMF-650 being a key candidate [11] - The company aims to improve the lives of patients suffering from metabolic diseases through innovative treatments [11] Product Details - BMF-650 has shown promising results in preclinical studies, demonstrating dose-dependent reductions in food intake and significant weight loss in obese cynomolgus monkeys [3][6] - In these studies, animals receiving 10 mg/kg and 30 mg/kg doses experienced average body weight reductions of approximately 12% and 15% respectively [3] - The drug has a favorable pharmacokinetic profile, with higher bioavailability and less inter-individual variability compared to other oral GLP-1 receptor agonists [6] Clinical Development - The Phase I trial will evaluate the safety, tolerability, and preliminary efficacy of BMF-650 in healthy overweight or obese participants, with results expected in the first half of 2026 [4] - Initial data from the trial will focus on 28-day weight loss outcomes at the highest dose [4] Market Context - Obesity is a chronic disease affecting over 40% of adults in the United States, leading to various health complications and a significant public health burden [8] - GLP-1 receptor agonists are recognized for their role in improving glycemic control and promoting weight loss in individuals with type 2 diabetes and obesity [10]

Core Insights - The conference call is led by Ramses Erdtmann, the President and Chief Operating Officer of Biomea, who will present the results from the COVALENT-111 study [3]. Group 1: Study Overview - The COVALENT-111 study is a randomized double-blind, placebo-controlled Phase II clinical trial [3]. - The study aims to assess the safety and tolerability profile of icovamenib in patients with type II diabetes, along with exploratory efficacy endpoints [3].

Market Overview - U.S. stocks traded higher, with the Dow Jones index gaining over 100 points, up 0.33% to 46,847.49, NASDAQ rose 0.11% to 22,967.90, and S&P 500 increased 0.15% to 6,750.64 [1] - Financials shares increased by 0.6%, while consumer discretionary stocks fell by 0.4% [1] Company Earnings - McCormick & Co reported Q3 earnings of 85 cents per share, exceeding the analyst consensus estimate of 81 cents per share, and quarterly sales of $1.724 billion, surpassing the estimate of $1.713 billion [2] - The company revised its FY2025 adjusted EPS guidance down from $3.03-$3.08 to $3.00-$3.05 [2] Commodity Market - Oil prices decreased by 0.1% to $61.64, while gold prices increased by 0.4% to $3,992.70 [5] - Silver prices fell by 0.1% to $48.420, and copper prices rose by 0.8% to $5.0760 [5] European Market - European shares were higher, with the eurozone's STOXX 600 gaining 0.2%, Spain's IBEX 35 Index up 0.2%, London's FTSE 100 rising 0.2%, Germany's DAX 40 increasing 0.2%, and France's CAC 40 gaining 0.3% [6] Notable Stock Movements - Galecto, Inc. shares surged 705% to $29.87, and Trilogy Metals Inc. shares rose 216% to $6.60 following the reversal of a decision blocking the Ambler Road Project in Alaska [7] - Zeta Network Group shares increased by 131% to $3.8400 after entering a strategic partnership with SOLV Foundation [7] - EPWK Holdings Ltd. shares dropped 61% to $0.1323 after announcing an $8 million public offering [7] - Connexa Sports Technologies Inc. shares fell 59% to $1.0350 after announcing a name change to AiRWA and receipt of $30 million in Solana tokens [7] - Biomea Fusion, Inc. shares decreased by 33% to $1.7950 following a public offering announcement [7] Asian Market - Asian markets closed higher, with Japan's Nikkei 225 gaining 0.01% and India's BSE Sensex increasing by 0.17% [8] Economic Indicators - The Redbook retail sales index rose by 5.8% year-over-year for the week ended October 4 [9]

Market Overview - U.S. stocks traded higher, with the Dow Jones index gaining over 100 points, up 0.33% to 46,847.49, NASDAQ rose 0.11% to 22,967.90, and S&P 500 increased 0.15% to 6,750.64 [1] - Financial shares increased by 0.6%, while consumer discretionary stocks fell by 0.4% [1] Company Earnings - McCormick & Co reported Q3 earnings of 85 cents per share, exceeding the analyst consensus estimate of 81 cents per share [2] - The company also reported quarterly sales of $1.724 billion, surpassing the analyst consensus estimate of $1.713 billion [2] - McCormick adjusted its FY2025 EPS guidance down from $3.03-$3.08 to $3.00-$3.05 [2] Commodity Market - Oil prices decreased by 0.1% to $61.64, while gold prices increased by 0.4% to $3,992.70 [5] - Silver prices fell by 0.1% to $48.420, and copper prices rose by 0.8% to $5.0760 [5] European Market - European shares were higher, with the eurozone's STOXX 600 gaining 0.2%, Spain's IBEX 35 Index up 0.2%, London's FTSE 100 up 0.2%, Germany's DAX 40 up 0.2%, and France's CAC 40 gaining 0.3% [6] Notable Stock Movements - Galecto, Inc. shares surged 705% to $29.87, and Trilogy Metals Inc. shares rose 216% to $6.60 following the reversal of a decision blocking the Ambler Road Project in Alaska [7] - Zeta Network Group shares increased by 131% to $3.8400 after entering a strategic partnership with SOLV Foundation [7] - EPWK Holdings Ltd. shares dropped 61% to $0.1323 after announcing an $8 million public offering [7] - Connexa Sports Technologies Inc. shares fell 59% to $1.0350 after announcing a name change to AiRWA and receipt of $30 million in Solana tokens [7] - Biomea Fusion, Inc. shares decreased by 33% to $1.7950 following a public offering announcement [7] Asian Market - Asian markets closed higher, with Japan's Nikkei 225 gaining 0.01% and India's BSE Sensex increasing by 0.17% [8] Economic Indicators - The Redbook retail sales index rose 5.8% year-over-year for the week ended October 4 [9]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Galecto, Inc. (GLTO) has seen a remarkable increase of 726%, trading at $30.67 [3] - C3is Inc. (CISS) is up 55%, currently priced at $3.43 [3] - Spruce Biosciences, Inc. (SPRB) has risen by 41%, trading at $184.00 [3] - Lexeo Therapeutics, Inc. (LXEO) is up 32%, priced at $8.60 [3] - Bluejay Diagnostics, Inc. (BJDX) has increased by 30%, trading at $2.03 [3] - Datavault AI Inc. (DVLT) is up 24%, currently at $2.58 [3] - Diginex Limited (DGNX) has risen by 13%, trading at $22.56 [3] - Global Interactive Technologies, Inc. (GITS) is up 13%, priced at $2.55 [3] - Odyssey Marine Exploration, Inc. (OMEX) has increased by 12%, trading at $3.00 [3] - AXIL Brands, Inc. (AXIL) is up 9%, currently at $6.16 [3] Premarket Losers - Society Pass Incorporated (SOPA) has decreased by 25%, trading at $3.94 [4] - SANUWAVE Health, Inc. (SNWV) is down 18%, currently priced at $33.30 [4] - Aehr Test Systems, Inc. (AEHR) has fallen by 18%, trading at $25.95 [4] - Aether Holdings, Inc. (ATHR) is down 16%, priced at $4.55 [4] - Dermata Therapeutics, Inc. (DRMA) has decreased by 13%, trading at $4.66 [4] - Lazydays Holdings, Inc. (GORV) is down 12%, currently at $2.55 [4] - OneMedNet Corporation (ONMD) has fallen by 11%, trading at $2.26 [4] - KORE Group Holdings, Inc. (KORE) is down 10%, priced at $2.53 [4] - Biomea Fusion, Inc. (BMEA) has decreased by 10%, trading at $2.38 [4] - CPS Technologies Corporation (CPSH) is down 9%, currently at $3.40 [4]

Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook. Contact: Meichiel Jennifer Weiss Sr. Director, Investor Relations and Corporate Development IR@biomeafusion.com Biomea is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic disease. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offe ...

Core Viewpoint - Biomea Fusion, Inc. (BMEA) has experienced a significant downtrend with a 19.3% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) for BMEA is currently at 26.33, indicating that the heavy selling pressure may be exhausting, which could lead to a price rebound [5]. - RSI is a momentum oscillator that helps identify whether a stock is oversold, typically when the reading falls below 30 [2][3]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts regarding BMEA, with a 1.7% increase in the consensus EPS estimate over the last 30 days, suggesting potential price appreciation [7]. - BMEA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a favorable outlook for a turnaround [8].